SYCREST received European Union (EU) approval from the European Medicines Agency (EMA) on September 1, 2010 for the treatment of moderate to severe manic episodes associated with bipolar I disorder in ...
Learn everything you need to know about Asenapine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...
Recognizing and Treating Prodrome in Bipolar Disorder A new analysis updated to include data from a fixed-dose, randomized, placebo-controlled Phase 3 trial of asenapine treatment for bipolar disorder ...
More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so ...
Review the side-effects of Asenapine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
New Data From a Separate Study Also Show Minimal Effect on Heart Rhythm Changes in Schizophrenia Patients VIENNA, Austria, Oct. 17 -- New data show that asenapine -- a psychopharmacologic agent being ...
Authors of a post-hoc analysis reported that asenapine is effective in the management of pediatric bipolar disorder regardless of the number of prior manic or mixed episodes. SAN ANTONIO, TX—The ...
Background: Asenapine demonstrated superiority over placebo for mania in bipolar I disorder patients experiencing acute current manic or mixed episodes in 2 randomized, placebo-and ...
Depression episode. Asenapine shown to decrease the time to recurrence of manic and depressive episodes among patients with bipolar I disorder. Asenapine was shown to decrease the time to recurrence ...
The District Court for the District of Delaware found Forest Labs’ patent for sublingual or buccal compositions of asenapine and methods of using such compositions to treat mental disorders, including ...
Akzo Nobel of the Netherlands has confirmed that the process has started for a listing of its pharmaceutical unit Organon and has appointed Morgan Stanley as global coordinator for the offer. Akzo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results